Summit plunges 70 percent as muscle-wasting disorder drug fails

(Reuters) - Britain's Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug, ezutromid, after it failed a mid-stage study, sending its shares plunging more than 70 percent.